Neoadjuvant hormonal therapy: The Canadian experience

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 56-64

  Labrie, Fernand ^a   Cusan, Leonello ^a   Gomez, Jose Luis ^a   Diamond, Pierre ^a   Suburu, Raul ^a   Lemay, Martin ^a   Tetu, Bernard ^a   Fradet, Yves ^a   Bélanger, Alain ^a   Candas, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFECT; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030934122     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00170-2     Document Type: Conference Paper

References (45)

1. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, and Candas B: Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44: 29-37, 1994.
2. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics 1996. CA Cancer J Clin 46: 5-27, 1996.
3. Brown ML, Fintor L, and Newman-Horm PA: The economic burden of cancer, in Greenwald P, Kramer B, Wed D (Eds): The Science and Practice of Cancer Prevention and Control. New York, Marcel Dekker, 1994.
4. Monfette G, Dupont A, and Labrie F: Temporary combination therapy with flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, in Labrie F, Lee F, Dupont A (Eds): Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. New York, Excerpta Medica, 1989, pp 41-51.
5. Lee F, Torp-Pedersen ST, Siders D, Littrup PJ, and McLeary RD: Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 170: 609-615, 1989.
6. Cooner WH, Mosley BR, Rutherford Jr, CLR, Beard JH, Pond HS, Terry WJ, Igel TC, and Kidd DD: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. Urology 143: 1146-1154, 1990.
7. Whitmore W: Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17: 689-697, 1990.
8. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
9. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 324: 1156-1161, 1991.
10. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, and Emond J: Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. J Urol 147: 846-852, 1992.
11. Lee F, Littrup PJ, Loft-Christensen L, Kelly BS, Jr, McHugh TA, Siders DB, Mitchell AE, and Newby JE: Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. Cancer 70(suppl): 211-220, 1992.
12. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M, and Têtu B: Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clin Invest Med 16: 425-439, 1993.
13. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emond J, Candas B: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16: 499-509, 1993.
14. Lee F, Siders DB, Newby JE, McHugh TA, and Solomon MH: The role of transrectal ultrasound-guided staging biopsy and androgen ablation therapy prior to radical prostatectomy. Clin Invest Med 16: 458-470, 1993.
15. Littrup PJ, Goodman AC, and Mettlin CJ: The benefit and cost of prostate cancer early detection. The Investivators of the American Cancer Society-National Prostate Cancer Project. CA Cancer J Clin 43: 134-149, 1993.
16. Mettlin C: Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project. Clin Invest Med 16: 440-447, 1993.
17. Kolata G: Prostate cancer consensus hampered by lack of data. Science 236: 1626-1627, 1987.
18. Walsh PC, and Jewett HJ: Radical surgery for prostatic cancer. Cancer 45: 1906-1911, 1980.
19. Jewett HJ, Bridge RW, Gray GF Jr, and Shelley WM: The palpable nodule of prostatic cancer. Results 15 years after radical excision. JAMA 203: 403-406, 1968.
20. Brawer MK, and Lange PH: Adjuvant therapy after radical prostatectomy. Probl Urol 4: 461-472, 1990.
21. Gibbons RP, Correa RJ Jr, Brannen GE, and Weissman RM: Total prostatectomy for clinically localized prostate cancer: long-term results. J Urol 141: 564-566, 1989.
22. Lange PH, and Narayan P: Understaging and under-grading of prostate cancer. Argument for postoperative radiation as adjuvant therapy. Urology 21: 113-118, 1983.
23. Catalona WJ, and Stein AJ: Staging errors in clinically localized prostatic cancer. J Urol 127: 452-456, 1982.
24. Veenema RJ, Gursel EO, and Lattimer JK: Radical retropubic prostatectomy for cancer: a 20-year experience. J Urol 117: 330-331, 1977.
25. Elder JS, Jewett HJ, and Walsh PC: Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol 127: 704-706, 1982.
26. Boxer RJ, Kaufman JJ, and Goodwin WE: Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients. J Urol 117: 208-213, 1977.
27. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tlc) prostate cancer. JAMA 271: 368-374, 1994.
28. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, and Oesterling JE: Clinical stage B0 or Tie prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology 41: 3-8, 1993.
29. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourĉière Y, Monfette G, Laberge JG, Emond J, Fazekas ATA, Raynaud JP, Husson JM: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. J Clin Invest Med 5: 267-275, 1982.
30. Labrie F, Dupont A, and Bélanger A: Complete androgen blockade for the treatment of prostate cancer, in de Vita VT, Hellman S, and Rosenberg SA, (Eds): Important Advances in Oncology. Philadelphia, J.B. Lippincott, 1985, pp 193-217.
31. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J, and Labrie C: Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16: 475-492, 1993.
32. Vaillancourt L, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, and Labrie F: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am J Surg Pathol 20: 86-93, 1996.
33. Radiation Therapy Oncology Group: Phase III trial of androgen suppression before and during radiation therapy for locally advanced prostatic cancer: abstract report of RTOG 8610. Prostate 5: 2-3, 1994.
34. Labrie F: Intracrinology and cancer therapy. Science Watch 5: 3-8,1994.
35. Boring CC, Squires TS, Tong T, and Montgomery S: Cancer statistics 1994. CA Cancer J Clin 44: 7-26, 1994.
36. Epstein JI, Paull G, Eggleston JC, and Walsh PC: Prognosis of untreated stage Al prostatic carcinoma: a study of 94 cases with extended follow-up. J Urol 136: 837-839, 1986.
37. Schröder FH, Denis L, Kirkels WJ, Koning HJ, and de Standaert B: European randomized study of screening for prostate cancer. Progress report of Antwerp and pilot studies. Cancer 76: 129-134, 1995.
38. Labrie F, Dupont A, Simard J, Luu-The V, and Bélanger A: Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 24(suppl 2): 94-105, 1993.
39. Brendler CB, and Walsh PC: The role of radical prostatectomy in the treatment of prostate cancer. CA Cancer J Clin 42: 212-222, 1992.
40. Solomon MH: Radical prostatectomy following androgen blockade, in Lee F, McLeary RL (Eds): Chicago, IL: Chicago University Press, 1990, p 100.
41. Schulman CC, and Sassine AN: Neoadjuvant hormonal deprivation before radical prostatectomy. Clin Invest Med 16: 523-531, 1993.
42. Fair WF, Aprikian AG, Cohen D, Sogani P, and Reuter V: Use of neoadjuvant androgen deprivation therapy in clinical localized prostate cancer. Clin Invest Med 16: 516-522, 1993.
43. Labrie F: Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am 20: 845-872, 1991.
44. Solomon MH, McHugh TA, Dorr RP, Lee F, and Siders DB: Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 16: 532-538, 1993.
45. Andros EA, Danesghari F, and Crawford ED: Neoadjuvant hormonal therapy in stage C carcinoma of the prostate. Clin Invest Med 16: 510-515, 1993.